CVS Health Corporation $CVS Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC cut its stake in shares of CVS Health Corporation (NYSE:CVS) by 2.2% during the first quarter, Holdings Channel reports. The firm owned 3,536,861 shares of the pharmacy operator’s stock after selling 80,085 shares during the quarter. Janus Henderson Group PLC’s holdings in CVS Health were worth $254,021,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. State Street Corp raised its holdings in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares in the last quarter. Legal & General Group Plc increased its position in shares of CVS Health by 0.3% during the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after buying an additional 31,249 shares during the period. Deutsche Bank AG increased its position in shares of CVS Health by 28.4% during the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock valued at $370,333,000 after buying an additional 1,031,998 shares during the period. KBC Group NV raised its stake in CVS Health by 200.4% in the fourth quarter. KBC Group NV now owns 676,809 shares of the pharmacy operator’s stock worth $53,711,000 after buying an additional 451,521 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. purchased a new stake in CVS Health in the fourth quarter worth about $3,333,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on CVS shares. Sanford C. Bernstein upped their target price on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Wells Fargo & Company raised their target price on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Argus upped their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Truist Financial increased their price objective on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, Bank of America raised their price objective on CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Twenty-one research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $105.67.

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Performance

CVS Health stock opened at $105.21 on Friday. CVS Health Corporation has a twelve month low of $61.19 and a twelve month high of $110.68. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $134.24 billion, a P/E ratio of 46.35, a PEG ratio of 1.03 and a beta of 0.61. The stock’s 50 day moving average is $101.22 and its 200 day moving average is $86.91.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the previous year, the business earned $2.25 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. CVS Health’s payout ratio is presently 117.18%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts expect CVS Health’s upcoming results to show earnings growth, supported by favorable estimates and recent positive estimate revisions. The outlook reinforces expectations that the company can continue its earnings recovery after reporting quarterly EPS and revenue above consensus in its latest report. CVS Health Earnings Expected to Grow
• Positive Sentiment: UnitedHealth’s second-quarter results—featuring improved margins, a lower medical cost ratio and raised earnings guidance—provide a constructive read-through for managed-care companies including CVS Health, suggesting industry cost pressures may be easing. UnitedHealth Turnaround Signal
• Positive Sentiment: CVS received the overall winner award and four gold awards at the 2026 US Customer Experience Awards, including recognition for AI innovation and consumer-centric culture. The recognition supports management’s efforts to improve customer engagement and digital operations, though it has limited immediate earnings impact. CVS Customer Experience Awards
• Positive Sentiment: CVS expanded its pharmacy offering to include common prescription medications for dogs and cats across approximately 9,000 stores, creating a potential new convenience and prescription-volume opportunity. Pet Medications Available at CVS Pharmacy
• Neutral Sentiment: Health100 earned accreditation for consumer data privacy and security, while CVS settled-related litigation involving X and the World Federation of Advertisers. Both developments may reduce reputational or compliance concerns but are unlikely to materially affect near-term earnings. Health100 Accreditation
• Negative Sentiment: Reports that the Trump administration may discontinue subsidies that help hold down Medicare Part D premiums in 2027 are weighing on health-insurance stocks. The change could increase pricing pressure, membership risk and medical-cost uncertainty for CVS’s Aetna business. Medicare Subsidy Report

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.